All Open Trials

Title
(Clinicaltrials.gov identifier with hyperlink)

Trial ID#

Disease Indication

Cell-Biologic Product

PI

Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 Attached to TCRz and 4-1BB Signaling Domains in Patients with Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated with Cell Therapy

13BT022

Pediatric Leukemia/
Lymphoma

Humanized CD19 redirected autologous T cells (huCART19)

Shannon Maude, MD PhD

A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia
(NCT02228096)

14BT022/ CCTL019B2205J

Pediatric ALL

Single dose of CTL019 transduced cells

Stephan Grupp,
MD PhD

Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
(NCT02650414)

15CT055

Pediatric ALL

Autologous T cells expressing CD22 chimeric antigen
receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB)

Stephan Grupp,
MD PhD

Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRζ and 4-1BB Signaling Domains in Patients with Chemotherapy Resistant of Refractory CD19+ Leukemia and Lymphoma.  (PEDIATRIC version)
(NCT01626495)

CHP959

Pediatric ALL

CD19 redirected autologous T cells (CART-19 T Cells)

Stephan Grupp,  MD PhD

A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients, With or Without the CCR5 delta-32 Mutation, Pre-treated with Cyclophosphamide
(NCT02388594)

SB-728mR

HIV

ZFN Modified CD4+ T Cells

Pablo Tebas, MD
David Porter, MD

HER-2/neu pulsed DC1 vaccine combined with trastuzumab for patients with DCIS
(NCT02336984)

UPCC03114

DCIS

DC Vaccine

Brian Czerniecki, MD, PhD

Dose Optimization Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART-19) in Patients With Relapsed or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)
(NCT01747486)

UPCC03712

Leukemia

CD19 redirected autologous T cells (CART-19-T Cells)

Noelle Frey, MD

Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Linked to TCRζ and 4-1BB Signaling Domains in Patients With Chemotherapy Relapsed or Refractory Hodgkin Lymphoma
(NCT02277522)

UPCC04414

Hodgkin Lymphoma

CD19 RNA redirected autologous T cells (RNA CART19 cells)

Jakub Svoboda, MD

Randomized Phase II Trial of CD3/CD28 Activated Id-KLH Primed Autologous Lymphocytes in Patients With Myeloma Undergoing Autologous Transplant
(NCT01426828)
[MD Anderson site is open; UPenn is closed]

UPCC07409

Myeloma

CD3/CD28 activated autologous lymphocytes

Edward Stadtmauer, MD (UPenn)
and
Muzaffar H. Qazilbash, MD (MD Anderson)

c-Met CAR in triple negative breast cancer
(NCT01837602)

UPCC13111

Breast Cancer

C-MET CAR RNA redirected T cells

Julia Tchou, MD PhD

Phase IIA Study of Redirected Autologous T Cells Engineered to contain Anti-CD19 Attached to TCRz and 4-1BB Signaling Domains in Patients with Chemotherapy Resistant or Refractory CD19+ Lymphoma
(NCT02030834)

UPCC13413

Non-Hodgkin Lymphoma

CD19 redirected autologous T cells (CART-19 or CTL019 cells)

Stephen Schuster, MD

Pilot Study Of Redirected Autologous T Cells Engineered To Contain an Anti-BCMA scFv Coupled To TCRζ And 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT02546167)

UPCC14415

Multiple Myeloma

CART-BCMA

Adam D Cohen, MD

Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
(NCT02640209)

UPCC18415

CLL/SLL

CART19 + Ibrutinib

Saar Gill, MD

Pilot Study of Autologous T-cells Redirected to Mesothelin and CD19 with a Chimeric Antigen Receptor in Patients with Metastatic Pancreatic Cancer
(NCT02465983)

UPCC19214

Pancreatic Cancer

Autologous CART-meso-19 T cells

Andrew Ko, MD

Phase II Study of redirected autologous T cells engineered to contain anti-CD19 attached to TCRz and 4-1BB signaling domains in patients with chemotherapy resistant or refractory acute lymphoblastic leukemia
(NCT02030847)

UPCC21413

Leukemia

CD19 redirected autologous T cells (CART-19-T Cells)

Noelle Frey, MD

Pilot Phase I HER-2 Pulsed-DC Vaccine to Prevent Recurrence for Patients with HER-2 Driven High Risk Invasive Breast Cancer
(NCT02110173)

UPCC25113

Breast Cancer

DC Vaccine

Brian Czerniecki, MD PhD

Pilot Phase 1 HER-2 Pulsed-DC Vaccine R-2 to Prevent Recurrence for Patients with HER-2 driven Invasive Breast Cancer Post Neo-adjuvant Therapy
(NCT02110199)

UPCC26113

Breast Cancer

DC Vaccine

Brian Czerniecki, MD PhD

Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
(NCT02588456)

UPCC31415

Acute Lymphoblastic Leukemia

Autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB)

Noelle Frey, MD

Pilot Study of Autologous T Cells Redirected to EGFRVIII - with A Chimeric Antigen Receptor in Patients with EGFRVIII+ Glioblastoma
(NCT02209376)

UPCC35313

Glioblastoma Multiform

CART- EGFRvIII cells are autologous T cells transduced with a lentiviral vector to express anti- EGFRvIII scFv 41BB:TCRζ

Donald M. O'Rourke, MD (UPenn)
Susan Chang, MD (UCSF)

 

Open Cancer Trials

Title
(Clinicaltrials.gov identifier with hyperlink)

Trial ID#

Disease Indication

Cell-Biologic Product

PI

Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 Attached to TCRz and 4-1BB Signaling Domains in Patients with Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated with Cell Therapy

13BT022

Pediatric Leukemia/
Lymphoma

Humanized CD19 redirected autologous T cells (huCART19)

Shannon Maude, MD PhD

A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia
(NCT02228096)

14BT022/ CCTL019B2205J

Pediatric ALL

Single dose of CTL019 transduced cells

Stephan Grupp,
MD PhD

Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
(NCT02650414)

15CT055

Pediatric ALL

Autologous T cells expressing CD22 chimeric antigen
receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB)

Stephan Grupp,
MD PhD

Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRζ and 4-1BB Signaling Domains in Patients with Chemotherapy Resistant of Refractory CD19+ Leukemia and Lymphoma.  (PEDIATRIC version)
(NCT01626495)

CHP959

Pediatric ALL

CD19 redirected autologous T cells (CART-19 T Cells)

Stephan Grupp,  MD PhD

HER-2/neu pulsed DC1 vaccine combined with trastuzumab for patients with DCIS
(NCT02336984)

UPCC03114

DCIS

DC Vaccine

Brian Czerniecki, MD, PhD

Dose Optimization Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART-19) in Patients With Relapsed or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)
(NCT01747486)

UPCC03712

Leukemia

CD19 redirected autologous T cells (CART-19-T Cells)

Noelle Frey, MD

Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Linked to TCRζ and 4-1BB Signaling Domains in Patients With Chemotherapy Relapsed or Refractory Hodgkin Lymphoma
(NCT02277522)

UPCC04414

Hodgkin Lymphoma

CD19 RNA redirected autologous T cells (RNA CART19 cells)

Jakub Svoboda, MD

Randomized Phase II Trial of CD3/CD28 Activated Id-KLH Primed Autologous Lymphocytes in Patients With Myeloma Undergoing Autologous Transplant
(NCT01426828)
[MD Anderson site is open; UPenn is closed]

UPCC07409

Myeloma

CD3/CD28 activated autologous lymphocytes

Edward Stadtmauer, MD (UPenn)
and
Muzaffar H. Qazilbash, MD (MD Anderson)

c-Met CAR in triple negative breast cancer
(NCT01837602)

UPCC13111

Breast Cancer

C-MET CAR RNA redirected T cells

Julia Tchou, MD PhD

Phase IIA Study of Redirected Autologous T Cells Engineered to contain Anti-CD19 Attached to TCRz and 4-1BB Signaling Domains in Patients with Chemotherapy Resistant or Refractory CD19+ Lymphoma
(NCT02030834)

UPCC13413

Non-Hodgkin Lymphoma

CD19 redirected autologous T cells (CART-19 or CTL019 cells)

Stephen Schuster, MD

Pilot Study Of Redirected Autologous T Cells Engineered To Contain an Anti-BCMA scFv Coupled To TCRζ And 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT02546167)

UPCC14415

Multiple Myeloma

CART-BCMA

Adam D Cohen, MD

Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
(NCT02640209)

UPCC18415

CLL/SLL

CART19 + Ibrutinib

Saar Gill, MD

Pilot Study of Autologous T-cells Redirected to Mesothelin and CD19 with a Chimeric Antigen Receptor in Patients with Metastatic Pancreatic Cancer
(NCT02465983)

UPCC19214

Pancreatic Cancer

Autologous CART-meso-19 T cells

Andrew Ko, MD

Phase II Study of redirected autologous T cells engineered to contain anti-CD19 attached to TCRz and 4-1BB signaling domains in patients with chemotherapy resistant or refractory acute lymphoblastic leukemia
(NCT02030847)

UPCC21413

Leukemia

CD19 redirected autologous T cells (CART-19-T Cells)

Noelle Frey, MD

Pilot Phase I HER-2 Pulsed-DC Vaccine to Prevent Recurrence for Patients with HER-2 Driven High Risk Invasive Breast Cancer
(NCT02110173)

UPCC25113

Breast Cancer

DC Vaccine

Brian Czerniecki, MD PhD

Pilot Phase 1 HER-2 Pulsed-DC Vaccine R-2 to Prevent Recurrence for Patients with HER-2 driven Invasive Breast Cancer Post Neo-adjuvant Therapy
(NCT02110199)

UPCC26113

Breast Cancer

DC Vaccine

Brian Czerniecki, MD PhD

Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
(NCT02588456)

UPCC31415

Acute Lymphoblastic Leukemia

Autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB)

Noelle Frey, MD

Pilot Study of Autologous T Cells Redirected to EGFRVIII - with A Chimeric Antigen Receptor in Patients with EGFRVIII+ Glioblastoma
(NCT02209376)

UPCC35313

Glioblastoma Multiform

CART- EGFRvIII cells are autologous T cells transduced with a lentiviral vector to express anti- EGFRvIII scFv 41BB:TCRζ

Donald M. O'Rourke, MD (UPenn)
Susan Chang, MD (UCSF)

 

Open HIV Trials

Title
(Clinicaltrials.gov identifier with hyperlink)

Trial ID#

Disease Indication

Cell-Biologic Product

PI

A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients, With or Without the CCR5 delta-32 Mutation, Pre-treated with Cyclophosphamide
(NCT02388594)

SB-728mR

HIV

ZFN Modified CD4+ T Cells

Pablo Tebas, MD
David Porter, MD